[In vitro and in vivo effects of recombinant human interleukin-3 on hematopoietic progenitor cells].
As part of a phase I/II clinical trial with recombinant human Interleukin-3 (rhIL-3), bone marrow and peripheral blood cells from patients treated with rhIL-3 were assessed in vitro for effects on the cycling status and frequencies of erythroid, myelomonocytic and multilineage progenitor cells. Treatment with rhIL-3 induced a pronounced increase in S-phase rate of BFU-E, CFU-GEMM and day 14 CFU-GM. Circulating CFU-GEMM and day 14 CFU-GM were increased on day 7 of therapy whereas circulating BFU-E were reduced in the majority of patients. After i.v. bolus injection of IL-3 an acute effect on the peripheral blood count with neutrophilia and, after an initial nadir, monocytosis was observed. IL-6 serum-levels increased in 5 out of 14 patients after IL-3 administration with concomitant side effects in 2 patients in whom IL-6 levels increased above 75 pg/ml. In the majority of the patients a stimulation of peripheral leukocytes and platelets was observed during the 15 day treatment course. In conclusion rhIL-3 induces a multilineage response in vivo by stimulating proliferation of hemopoietic progenitor cells with a resulting elevation in peripheral blood counts.
Seipelt
G
G
Abteilung für Hämatologie, J. W. v. Goethe-Universität, Frankfurt.
Ottmann
O G
OG
Ganser
A
A
Eder
M
M
Lindemann
A
A
Falk
S
S
Stutte
H J
HJ
Hübner
K
K
Mertelsmann
R
R
Hoelzer
D
D
D001853:Bone Marrow / Q000473:pathology; D004341:Drug Evaluation; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007377:Interleukin-3 / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D007377:Interleukin-3; D011994:Recombinant Proteins
In vitro und in vivo Effekte des rekombinanten humanen Interleukin-3 auf hämatopoietische Progenitorzellen.